Jujuboside B

Synonyms: 酸枣仁皂苷B
Jujuboside B 是一种可从酸枣仁 (Ziziphi Spinosae Semen) 中分离得到的具有生物活性的皂苷成分,具有口服有效性和血脑屏障通透性,可通过激活 RIPK1/RIPK3/MLKL 通路诱导急性白血病细胞死亡并驱动坏死性凋亡 (Apoptosis),通过上调 NOXA、PARP 及 caspase-3 的表达、激活 AMPK 抑制乳腺癌细胞增殖并诱导细胞凋亡和自噬 (Autophagy),通过阻断 VEGFR-2 信号通路抑制血管生成和肿瘤生长,通过调控 Nrf2-STING 信号通路缓解小鼠肝损伤,通过调控抗炎反应、下调 11β-HSD2 表达缓解肝脏损伤,通过非小细胞肺癌中的 PPARγ-ATF3-Gpx4 信号通路诱导铁死亡 (Ferroptosis) 并克服放疗抵抗,具有抑制血小板聚集的作用,通过抑制 AMPA 受体活性抑制热性惊厥,并通过阻断 PI3K/Akt 和 MAPK/ERK 通路及使 CREB 信号去磷酸化逆转慢性不可预知温和应激促进的肿瘤进展,可用于急性白血病、乳腺癌、PM2.5 诱导的肺损伤、肝毒性、肝损伤、结直肠癌、非小细胞肺癌、血栓栓塞性疾病、血小板高聚集相关心血管疾病、热性惊厥以及类抑郁表型的相关研究。
产品编号: MS-Q74849 纯度: 99.92% CAS No.: 55466-05-2 分子式: C52H84O21 分子量: 1045.21
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Jujuboside B 是一种可从酸枣仁 (Ziziphi Spinosae Semen) 中分离得到的具有生物活性的皂苷成分,具有口服有效性和血脑屏障通透性,可通过激活 RIPK1/RIPK3/MLKL 通路诱导急性白血病细胞死亡并驱动坏死性凋亡 (Apoptosis),通过上调 NOXA、PARP 及 caspase-3 的表达、激活 AMPK 抑制乳腺癌细胞增殖并诱导细胞凋亡和自噬 (Autophagy),通过阻断 VEGFR-2 信号通路抑制血管生成和肿瘤生长,通过调控 Nrf2-STING 信号通路缓解小鼠肝损伤,通过调控抗炎反应、下调 11β-HSD2 表达缓解肝脏损伤,通过非小细胞肺癌中的 PPARγ-ATF3-Gpx4 信号通路诱导铁死亡 (Ferroptosis) 并克服放疗抵抗,具有抑制血小板聚集的作用,通过抑制 AMPA 受体活性抑制热性惊厥,并通过阻断 PI3K/Akt 和 MAPK/ERK 通路及使 CREB 信号去磷酸化逆转慢性不可预知温和应激促进的肿瘤进展,可用于急性白血病、乳腺癌、PM2.5 诱导的肺损伤、肝毒性、肝损伤、结直肠癌、非小细胞肺癌、血栓栓塞性疾病、血小板高聚集相关心血管疾病、热性惊厥以及类抑郁表型的相关研究。

生物实验数据

生物活性 Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen with oral efficacy and blood-brain barrier permeability, which induces acute leukemia cell death and drives necroptosis (Apoptosis) by activating the RIPK1/RIPK3/MLKL pathway, inhibits breast cancer cell proliferation and induces apoptosis and autophagy (Autophagy) by upregulating the expression of NOXA, PARP, and caspase-3 and activating AMPK, inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway, alleviates mouse liver injury by regulating the Nrf2-STING signaling pathway, alleviates liver injury by regulating anti-inflammatory responses and downregulating 11β-HSD2 expression, induces ferroptosis (Ferroptosis) and overcomes radiotherapy resistance through the PPARγ-ATF3-Gpx4 signaling pathway in non-small cell lung cancer, exhibits inhibitory effects on platelet aggregation, suppresses febrile seizures by inhibiting AMPA receptor activity, and reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling, and can be used for research related to acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, platelet hyperaggregation-related cardiovascular diseases, febrile seizures, and depression-like phenotypes.
体外研究
(In Vitro)

Jujuboside B (40-200 μM; 24-72 h) 可呈剂量和时间依赖性降低 U937、HL-60、Jurkat 和 Kasumi-1 急性白血病细胞系的活力,降低原代人急性髓系白血病 (AML) 细胞的存活率。
Jujuboside B (0-120 μM; 2 weeks) 可显著降低 U937 急性白血病细胞的克隆形成能力。
Jujuboside B (40-120 μM; 24 h) 通过 RIPK1/RIPK3/MLKL 通路介导 U937 急性白血病细胞发生坏死性凋亡,上调 U937 急性白血病细胞中 RIPK1、RIPK3 和 MLKL 的总蛋白水平与磷酸化水平。
Jujuboside B (20-100 μM; 72 h) 可强效抑制 MDA-MB-231 (IC50 = 54.38 μM) 和 MCF-7 (IC50 = 74.94 μM) 人乳腺癌细胞的增殖,处理时间为 72 h。
Jujuboside B (25-75 μM; 10-14 days) 可降低 MDA-MB-231 和 MCF-7 人乳腺癌细胞的克隆形成存活率。
Jujuboside B (25-75 μM; 16-48 h) 可呈剂量依赖性地抑制人乳腺癌 MDA-MB-231 细胞的迁移,诱导人乳腺癌细胞 MDA-MB-231 和 MCF-7 发生剂量依赖性凋亡,上调人 MDA-MB-231 细胞和 MCF-7 细胞中凋亡标志物剪切型 PARP 及剪切型 caspase-3 的表达,上调 MDA-MB-231 和 MCF-7 中 NOXA 的表达,激活 AMPK。
Jujuboside B (25-75 μM; 12-48 h) 可在人乳腺癌细胞 MDA-MB-231 和 MCF-7 中诱导呈剂量依赖性和时间依赖性的自噬,增强LC3-I 向 LC3-II 的转化以及降低 p62 表达水平,在人乳腺癌 MCF-7 细胞中呈 AMPK 依赖性诱导自噬。
Jujuboside B (1-100 μM; 8-48 h) 可剂量依赖性地抑制 HUVEC 的细胞活力,抑制 HUVEC 的迁移,抑制 Matrigel 上 HUVEC 的管形成,而对 HCT-15 细胞活力的影响极小。
Jujuboside B (1-100 μM; 24 h) 可呈剂量依赖性地将 HUVECs 阻滞于细胞周期的 G0/G1 期。
Jujuboside B (1-100 μM; 30 min pre-incubation) 可呈剂量依赖性地阻断 VEGF165 诱导的 HUVEC 中 VEGFR2 及其下游介导因子 (Akt、FAK、Src、PLCγ1) 的磷酸化。
Jujuboside B (100 μM; 24 h) 在 A549 和 H460 细胞中对 100 ng/mL DR4 和 DR5 蛋白水平的调控效果优于单独处理。
Jujuboside B (30-300 μM; 5 min) 可剂量依赖性地抑制胶原、凝血酶、Arachidonic acid (AA) (MS-A69140) 和二磷酸腺苷 (ADP) 诱导的大鼠富血小板血浆聚集,其中对胶原、凝血酶和 AA 诱导的聚集的 IC50 值分别为 92.1 μM、201.5 μM 和 95.2 μM,且在 300 μM 浓度下不会产生血小板细胞毒性。
Jujuboside B (30-300 μM; 预处理 5 分钟,胶原孵育 6 分钟) 抑制胶原诱导的大鼠富血小板血浆中 TXA2 的生成。
Jujuboside B (30-100 μM) 可在体外以剂量依赖的方式抑制 HEK293 细胞中重组 GluA1/GluA2 AMPA 受体的电流。
Jujuboside B (AMPA 刺激前预孵育 1 min,浓度 10 μM) 可显著抑制原代培养大鼠皮质神经元中 AMPA 诱导的细胞内钙升高,降低钙反应的峰值和累积值。
Jujuboside B (20-100 μM; 60 μM for viability, colony formation, pathway analysis) 可抑制 A549 细胞的活力与集落形成,并通过降低关键通路组分的磷酸化水平阻断 PI3K/Akt 和 MAPK/ERK 信号通路,其 IC50 为 60 μM。

Cell Viability Assay

Cell Line: U937, HL-60, Jurkat, Kasumi-1 acute leukemia cell lines
Concentration: 40, 80, 100, 120, 160, 200 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Inhibited the growth of all four leukemia cell lines in a dose- and time-dependent manner.
Showed significant inhibitory effects after 24-h treatment, with potency increasing at longer incubation times.

Cell Proliferation Assay

Cell Line: U937 acute leukemia cells
Concentration: 40, 80, 120 μM
Incubation Time: 2 weeks
Result: Significantly inhibited colony formation of U937 cells at 80 μM and 120 μM, reflected by decreased colony number and size.
Did not significantly affect colony counts at 40 μM.

Western Blot Analysis

Cell Line: U937 acute leukemia cells
Concentration: 40, 80, 120 μM
Incubation Time: 24 h
Result: Significantly increased protein levels of RIPK1, p-RIPK1, RIPK3, p-RIPK3, MLKL, and p-MLKL in U937 cells in a dose-dependent manner.
Induced statistically significant upregulation of all target proteins and their phosphorylated forms at 80 μM and 120 μM.

Cell Viability Assay

Cell Line: MDA-MB-231, MCF-7 human breast cancer cell lines
Concentration: 0, 40, 60, 80, and 100 μM
Incubation Time: 72 h
Result: Significantly inhibited the proliferation of MDA-MB-231 and MCF-7 in a dose-dependent manner.
Achieved an IC50 of 54.38 μM for MDA-MB-231 and 74.94 μM for MCF-7.

Cell Migration Assay

Cell Line: MDA-MB-231 human breast cancer cell line
Concentration: 25, 50, 75 μM
Incubation Time: 16 h
Result: Inhibited the migration of MDA-MB-231 cells in a dose-dependent manner, with significant reductions in migrated cell numbers at all tested concentrations.

Apoptosis Analysis

Cell Line: MDA-MB-231, MCF-7 human breast cancer cell lines
Concentration: 25, 50, 75 μM
Incubation Time: 48 h
Result: Resulted in a remarkable dose-dependent increase in the apoptotic cell population (early apoptotic Annexin V(+)/PI(−) and late apoptotic Annexin V(+)/PI(+) cells) in both cell lines.

Western Blot Analysis

Cell Line: MDA-MB-231, MCF-7 human breast cancer cell lines
Concentration: 25, 50, 75 μM
Incubation Time: 48 h
Result: Significantly increased the expression of cleaved PARP and cleaved caspase-3 in a dose-dependent manner in both cell lines.\nRemarkably elevated NOXA expression in a dose-dependent pattern in both cell lines.\nIncreased phosphorylated AMPK levels in a dose-dependent manner in both cell lines.

Western Blot Analysis

Cell Line: MDA-MB-231, MCF-7 human breast cancer cell lines
Concentration: 25-75 μM (48 h treatment); 50 μM (12-48 h treatment)
Incubation Time: 48 h (dose-dependent autophagy); 12-48 h (time-dependent autophagy)
Result: Increased the conversion of LC3-I to LC3-II in a dose-dependent manner after 48 h of treatment.
Accumulated LC3-II in a time-dependent manner from 12 to 48 h of treatment at 50 μM.
Decreased p62 expression in a dose-dependent manner after 48 h of treatment in both cell lines.

Cell Viability Assay

Cell Line: human umbilical vein endothelial cells (HUVECs), HCT-15 human colorectal adenocarcinoma cells
Concentration: 1, 3, 10, 30, and 100 μM
Incubation Time: 48 h
Result: Significantly suppressed HUVEC viability in a dose-dependent manner, with minimal effect at 1-10 μM and strong suppression at ≥30 μM.
Maintained over 65% of HCT-15 cell viability across all tested concentrations.

Cell Cycle Analysis

Cell Line: HUVECs
Concentration: 1, 3, 10, 30, and 100 μM
Incubation Time: 24 h
Result: Caused dose-dependent changes in the percentage of cells in G0/G1 and S phases, indicating G0/G1 phase arrest.

Cell Migration Assay

Cell Line: HUVECs
Concentration: 1, 3, 10, 30, and 100 μM
Incubation Time: 10 h
Result: Inhibited HUVEC migration in a dose-dependent manner, with ~20% inhibition at 3 μM and ~90% inhibition at 100 μM.

Western Blot Analysis

Cell Line: HUVECs
Concentration: 1, 3, 10, 30, and 100 μM
Incubation Time: 30 min (pre-incubation prior to VEGF165 stimulation)
Result: Inhibited phosphorylation of VEGFR2 in a dose-dependent manner.
Inhibited phosphorylation of downstream signaling proteins (Akt, FAK, Src, PLCγ1) in a dose-dependent manner.

Western Blot Analysis

Cell Line: A549, H460
Concentration: 100 μM (combined with 100 ng/mL TRAIL)
Incubation Time: 24 h
Result: Upregulated DR4 and DR5 protein levels more significantly than jujuboside B or TRAIL alone in A549 and H460 cells.
体内研究
(In Vivo)

Jujuboside B (i.p.;每日 1 次;连续 17 天;20 mg/kg) 可显著抑制裸鼠体内 MCF-7、MDA-MB-231 乳腺癌异种移植物的生长,同时会诱导肿瘤细胞凋亡和自噬,且未观察到对动物体重产生影响。
Jujuboside B (0.1-0.8 mg/kg;i.v.;2 天内 3 次) 可通过调控 TLR2/4-MyD88 及 mTOR-自噬通路,减轻炎症、细胞凋亡与自噬功能障碍,从而显著缓解 BALB/c 小鼠中 PM2.5 诱导的肺损伤。
Jujuboside B (i.p./i.v.;每日 1 次;连续 7 天/单次给药,20-40 mg/kg/0.4-1.5 mg/kg) 可剂量依赖性地改善 Acetaminophen (MS-H20928 ) 诱导的雄性 C57BL/6 J 小鼠急性肝损伤,同时抑制氧化应激、炎症反应、细胞凋亡及 STING 通路激活,并激活 Nrf2 通路;可通过减轻炎症、增强抗氧化能力、上调 GR 表达以及下调 11β-HSD2 表达,呈剂量依赖性地保护雄性 C57BL/6 小鼠免受盲肠结扎穿孔术 (CLP) 诱导的肝损伤。
Jujuboside B (i.p.,每 2 天 1 次,7 次,剂量为 20 mg/kg) 可通过抗血管生成和抗增殖机制使雌性 BALB/c 裸鼠的皮下 HCT-15 结直肠癌肿瘤体积减少 55.5%、肿瘤重量降低 56.3%,且未观察到与治疗相关的体重减轻。
Jujuboside B (1–100 μM) 局部作用于鸡胚尿囊膜时,可呈剂量依赖性抑制新生血管生成,100 μM 浓度下抑制率可达 80%。
Jujuboside B (10-100 μM; 掺入皮下 Matrigel 栓) 被掺入皮下 Matrigel 栓后,可呈剂量依赖性抑制雌性 BALB/c 小鼠体内 VEGF 诱导的血管生成。
Jujuboside B (i.p.,每隔 1 天 1 次,20-40 mg/kg) 可呈剂量依赖性地减小裸鼠体内 A549 非小细胞肺癌的肿瘤体积,且不会引发明显的肝毒性或肾毒性。
Jujuboside B (10-100 mg/kg;p.o.;单次给药) 可对雄性 ICR 小鼠中由胶原蛋白和肾上腺素诱导的急性肺血栓栓塞提供具有统计学显著性的 63%保护作用。
Jujuboside B (10-50 mg/kg;i.p.;高热诱导前 1 小时单次给药) 可剂量依赖性地抑制 P14 雄性 C57BL/6 小鼠的热性惊厥严重程度。
Jujuboside B (40 mg/kg/天;i.p.;每日;持续 2 周) 可通过调控凋亡相关蛋白、阻断 PI3K/Akt 及 MAPK/ERK 信号通路、降低炎性细胞因子水平,在非应激和 CUMS 应激荷瘤雌性 C57BL/6 小鼠中显著抑制肺癌进展。
Jujuboside B (40 mg/kg;i.p.;每日;持续 2 周) 可通过提升血清 5-HT 与色氨酸水平、改善行为学评分及降低炎症细胞因子水平,显著改善经 CUMS 造模的雌性 C57BL/6 小鼠的抑郁样行为。

Animal Model: athymic BALB/c nude (female, 5-6-week-old)
Dosage: 20 mg/kg
Administration: i.p.; daily; 17,28 days
Result: Significantly inhibited MCF-7 tumor growth, with tumor volumes and final tumor weights markedly lower than the control group.
Showed no significant difference in animal body weight compared with the control group.
Elevated expression of cleaved PARP, cleaved caspase-3, and LC3-II in tumor tissue, indicating induction of apoptosis and autophagy.
Significantly inhibited MDA-MB-231 tumor growth, with tumor volumes and final tumor weights markedly lower than the control group.
Showed no significant difference in animal body weight compared with the control group.
Elevated expression of cleaved PARP, cleaved caspase-3, and LC3-II in tumor tissue, indicating induction of apoptosis and autophagy.
Animal Model: BALB/c (7-week-old; acclimated for 12 days; PM2.5-induced lung injury model)
Dosage: 0.1 mg/kg; 0.4 mg/kg; 0.8 mg/kg
Administration: i.v.; three times over 2 days
Result: Significantly reduced the PM2.5-induced increase in lung wet/dry weight ratio, total cell count in BALF, total neutrophil count in BALF, and lung injury score.
Significantly reversed PM2.5-induced changes in apoptotic protein levels: restored anti-apoptotic Bcl-2 levels, reduced pro-apoptotic Bax, cleaved caspase-3, and cleaved PARP levels, and decreased the TUNEL-positive apoptotic cell percentage.
Significantly reduced PM2.5-induced increases in pro-inflammatory cytokines IFN-γ, IL-1β, IL-6, IL-18, and TNF-α, and restored PM2.5-induced decreases in anti-inflammatory cytokines IL-2, IL-4, and IL-10.
Significantly inhibited PM2.5-induced upregulation of autophagy-related proteins LC3 II and Beclin 1, reversed PM2.5-induced increases in TLR2, TLR4, and MyD88 levels, and restored PM2.5-induced reductions in phosphorylated mTOR, Akt, and PI3K levels.
Animal Model: C57BL/6 J (male, 8 weeks old, Acetaminophen-induced acute hepatotoxicity)
Dosage: 20 mg/kg; 40 mg/kg
Administration: i.p.; daily; 7 days
Result: Reversed acetaminophen-induced CYP2E1 upregulation in liver tissue in a dose-dependent manner.
Reduced acetaminophen-induced mortality from 80% to 30% over 48 hours (40 mg/kg dose).
Dose-dependently reduced serum ALT, AST, and LDH levels, improved liver histopathological scores, and attenuated liver tissue necrosis compared to acetaminophen-only controls.
Dose-dependently suppressed acetaminophen-induced increases in serum and liver TNF-α, IL-6, and IFN-β levels, reduced liver macrophage infiltration (F4/80-positive cells), and lowered liver TNF-α and IL-6 protein expression.
Dose-dependently reversed acetaminophen-induced increases in liver 4-HNE and MDA levels, restored liver GSH, SOD, and CAT activities, upregulated liver SOD1 and SOD2 mRNA levels, downregulated liver NOX2 and COX2 mRNA levels, reduced hepatocyte apoptosis (increased Bcl-2/Bax ratio, decreased cleaved caspase-3), inhibited acetaminophen-induced STING pathway activation (reduced STING, p-IRF3, and p-p65 protein levels in liver tissue), and activated the Nrf2 pathway (increased total, nuclear, and cytosolic Nrf2 protein levels, upregulated liver HO-1 and NQO-1 protein and mRNA levels).
Animal Model: C57BL/6 (male, 8-10 weeks old, average weight 27 g, CLP-induced sepsis)
Dosage: 0.4 mg/kg; 0.75 mg/kg; 1.5 mg/kg
Administration: i.v.; single dose
Result: Significantly reduced CLP-induced hepatic histopathological damage, including hemorrhagic necrosis, portal inflammation, parenchymal necrosis, and inflammatory cell infiltration at 0.75 mg/kg and 1.5 mg/kg.
Significantly reduced elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at 0.75 mg/kg and 1.5 mg/kg.
Significantly reduced elevated liver tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and nitric oxide (NO) levels at 0.75 mg/kg and 1.5 mg/kg; significantly reduced elevated liver TNF-α and NO levels at 0.4 mg/kg.
Reduced elevated liver malondialdehyde (MDA) levels at 0.75 mg/kg and 1.5 mg/kg.
Restored reduced liver glutathione (GSH), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activity at 0.75 mg/kg and 1.5 mg/kg.
Increased reduced liver glucocorticoid receptor (GR) protein expression at 0.4 mg/kg, 0.75 mg/kg, and 1.5 mg/kg.
Reduced elevated liver 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) protein expression, with no effect on 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) expression at 0.75 mg/kg and 1.5 mg/kg.
Did not significantly reduce serum ALT/AST levels or liver IL-1β levels at 0.4 mg/kg.
Animal Model: BALB/c nude (female)
Dosage: 20 mg/kg
Administration: i.p.; once every two days; 7 total doses
Result: Reduced mean tumor volume by 55.5% compared to control group.
Reduced mean tumor weight by 56.3% compared to control group.
Significantly reduced tumor microvessel density.
Significantly decreased Ki67-positive proliferative tumor cells.
Significantly increased tumor necrosis area relative to controls.
Caused no significant mouse body weight loss during treatment.
Animal Model: BALB/c nude (female, 6 weeks old)
Dosage: 20 mg/kg; 40 mg/kg
Administration: i.p.; every other day
Result: Reduced tumor volumes in a dose-dependent manner relative to controls, with statistically significant reductions observed over the study period.
Showed no significant difference in body weights between treated and control groups.
Exhibited no significant difference in serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CRE) from controls.
Animal Model: ICR mice (male, 35-40 g)
Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg
Administration: p.o.; single dose
Result: Provided 17% protection against thromboembolism.
Provided 43% protection against thromboembolism.
Provided 63% protection against thromboembolism, which was statistically significant compared to vehicle.
Animal Model: C57BL/6 (male, postnatal day 14, 6-7 g, LPS-primed hyperthermic induction)
Dosage: 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration: i.p.; single dose 1 hour before hyperthermic induction
Result: Increased seizure latency to 228.7, reduced the percentage of grade 5 seizures to 50%, and decreased seizure severity (Racine score) to 4.5.
Significantly prolonged seizure latency to 563.3s, eliminated grade 5 seizures (90% of mice exhibited maximum grade 3 seizures), decreased seizure severity (Racine score) to 2.9, prolonged latency to EEG seizure onset to 680.0s, shortened total seizure duration to 551.9s, decreased seizure spike number to 39.88, and reduced hippocampal c-Fos-positive cells to 15.50 cells/mm2.
Significantly prolonged seizure latency to 737.2 s, eliminated grade 5 seizures (80% of mice exhibited maximum grade 3 seizures), and decreased seizure severity (Racine score) to 2.8.
Animal Model: C57BL/6 (female, 8 weeks old, subcutaneous inoculation of LLC lung cancer cells; chronic unpredictable mild stress exposure)
Dosage: 40 mg/kg/day
Administration: i.p.; daily; 2 weeks
Result: Significantly reduced tumor volume and weight compared to vehicle controls in non-CUMS tumor-bearing mice.
Significantly reduced tumor volume and weight compared to vehicle-treated CUMS-exposed tumor-bearing mice, reversing CUMS-promoted tumor progression.
Significantly increased proapoptotic Bax protein and mRNA expression, and decreased antiapoptotic Bcl-2 protein and mRNA expression in tumor tissues compared to corresponding vehicle controls.
Significantly reduced phosphorylation levels of PI3K, Akt, MAPK, ERK, and CREB in tumor tissues compared to corresponding vehicle controls.
Significantly decreased serum levels of inflammatory cytokines TNF-α, IL-4, IL-6, and IL-10 compared to vehicle controls.
Animal Model: C57BL/6 (female, 8 weeks old, chronic unpredictable mild stress exposure)
Dosage: 40 mg/kg/day
Administration: i.p.; daily; 2 weeks
Result: Significantly increased serum 5-HT and tryptophan levels compared to vehicle-treated CUMS-exposed mice.
Significantly increased sucrose preference, locomotion scores, and exploratory scores compared to vehicle-treated CUMS-exposed mice, ameliorating depression-like phenotypes.
Significantly decreased serum levels of inflammatory cytokines TNF-α, IL-4, IL-6, and IL-10 compared to vehicle controls.
性状 固体
颜色 White to off-white

化学信息

分子量 1045.21
分子式 C52H84O21
CAS No. 55466-05-2
别名 酸枣仁皂苷B

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.91 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (9.57 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (95.67 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9567 mL4.7837 mL9.5675 mL23.9186 mL
5 mM0.1913 mL0.9567 mL1.9135 mL4.7837 mL
10 mM0.0957 mL0.4784 mL0.9567 mL2.3919 mL
15 mM0.0638 mL0.3189 mL0.6378 mL1.5946 mL
20 mM0.0478 mL0.2392 mL0.4784 mL1.1959 mL
25 mM0.0383 mL0.1913 mL0.3827 mL0.9567 mL
30 mM0.0319 mL0.1595 mL0.3189 mL0.7973 mL
40 mM0.0239 mL0.1196 mL0.2392 mL0.5980 mL
50 mM0.0191 mL0.0957 mL0.1913 mL0.4784 mL
60 mM0.0159 mL0.0797 mL0.1595 mL0.3986 mL
80 mM0.0120 mL0.0598 mL0.1196 mL0.2990 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础